Ronald Elgersma

Director, Protein & Medicinal Chemistry Byondis

Seminars

Tuesday 4th November 2025
Showcasing Preclinical Development of Byondis’ Antifolate Linker-Drug ADCs
11:00 am
  • Presenting development of a novel antifolate linker-drug platform, a toxin class with a clinically validated mechanism of action
  • Discussing preclinical development of antifolate-based ADCs across in vitro and in vivo studies
  • Outlining antifolate payload mechanism of action and physicochemical properties
Ronald Elgersma - 16th World ADC San Diego